Shares of aTyr Pharma, Inc. (LIFE) stock were popping high in the pre-market trading session today on September 14, 2021. It seems that the stock is continuing the previously bullish sentiment after the release of positive data from Phase 1b/2a Clinical Trial of ATYR1923. LIFE stock saw a surge of 13.11% to reach $10.35 a share at the time of this writing. The stock soared by 66.97% at the previous closing bringing its per-share price to $9.15. Let’s dig in to explore more about this stock.
aTyr Pharma, Inc is the biotherapeutics stock that discovers and develops therapeutics in the U.S based on novel immunological pathways. Its lead product candidate is ATYR1923 which treats patients with lung diseases and other respiratory issues due to Covid-19. Its other main product is ATYR2810 to treat patients with aggressive cancers.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Key News of LIFE stock:
Yesterday LIFE stock released data of phase 1b/2a Clinical Trial that demonstrated consistent ATYR1923 dose-response in Pulmonary Sarcoidosis. 37 patients participated in the study and data represented well tolerance as well as safety profile at all doses. The study team observed no serious adverse event or signal of immunogenicity. ATYR1923 showed consistent dose-response on key efficacy endpoints and improvements as compared to placebo.
The management is very happy with the results of the study. The safety profile and consistent dose-response reflect that ATYR1923 will prove to be a disease-modifying therapy for pulmonary sarcoidosis. The management is planning to present the data to along with future clinical development plans to the U.S Food and Drug Administration. The registrational trial is expected to initiate in the next year.
Financial View of LIFE stock:
aTyr Pharma on August 10, 2021, did announce second-quarter 2021 financial results according to which
- LIFE stock suffered a $0.64 per share quarterly loss as compared to $0.69 per share in the same prior-year period.
- LIFE stock reported $7.7 million in research and development expenses in the second quarter of 2021. The major portion of these expenses is attributable to ATYR1923 and ATYR2810 program
- The stock spent $2.8 million in general and administrative expenses in the recently reported quarter.
- By the end of the second quarter of 2021, aTyr Pharma had $44.1 million in cash and cash equivalents.
Investors are responding positively to the LIFE stock after the release of positive data of Phase 1b/2a Clinical Trial of ATYR1923. aTyr Pharma has progressed well in 2021 as it gained almost 130% year-to-date. In a nutshell, this stock can be a good bet for long-term investors.